HCG Q4 Revenue Up 11% YoY, FY26 Growth at 15%

HCG reported Q4FY26 revenue of INR 6,523 Mn, up 11% YoY, and FY26 revenue of INR 25,454 Mn, up 15% YoY.
Adjusted EBITDA for FY26 stood at INR 4,711 Mn, up 19% YoY, with margin expansion of 68 bps to 18.5%.
The company announced the divestment of its non-core fertility business, Milann, for an enterprise valuation of INR 632 Mn.
A rights issue raised INR 4,250 Mn, strengthening the balance sheet and reducing net debt to INR 3,387 Mn.